Skip to main content
Clinical Trials/2024-510912-66-00
2024-510912-66-00
Recruiting
Phase 4

Local Levobupivacaine for pain relief after Endoscopic Submucosal Dissection for esophageal lesions: a Randomized Controlled Trial

Sint Antonius Ziekenhuis Stichting4 sites in 1 country84 target enrollmentStarted: August 23, 2024Last updated:

Overview

Phase
Phase 4
Status
Recruiting
Enrollment
84
Locations
4
Primary Endpoint
The proportion of patients with major pain within 90 minutes after the procedure comparing the LB and non-LB group. Major pain is defined as a score of four or higher based on a 0-10 NRS. The peak pain score (maximum reported pain score) at one of the three pre-defined time points of 30, 60 and 90 minutes after the procedure will be used for this.

Overview

Brief Summary

To evaluate the efficacy of local injection of levobupivacaine during esophageal ESD for direct post-procedural pain relief (within 90 minutes after ESD).

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients age ≥18 years at time of consent
  • Visible lesion in the esophagus, minimum diameter of the lesion ≥20 mm
  • Scheduled for esophageal ESD
  • Informed consent

Exclusion Criteria

  • Presence of multiple lesions requiring two or more separate endoscopic resections
  • Allergy to LB or other amide-type local anaesthesia
  • Current regular use of opioids
  • Other aetiology causing pain similar to post-ESD pain
  • Pregnancy or breast feeding
  • Inability to assess pain due to severe psychiatric or neurological disease
  • Insufficient command of Dutch language
  • History of esophageal surgery other than fundoplications
  • History of esophageal ablation therapy
  • History of radiotherapy of the esophagus

Outcomes

Primary Outcomes

The proportion of patients with major pain within 90 minutes after the procedure comparing the LB and non-LB group. Major pain is defined as a score of four or higher based on a 0-10 NRS. The peak pain score (maximum reported pain score) at one of the three pre-defined time points of 30, 60 and 90 minutes after the procedure will be used for this.

The proportion of patients with major pain within 90 minutes after the procedure comparing the LB and non-LB group. Major pain is defined as a score of four or higher based on a 0-10 NRS. The peak pain score (maximum reported pain score) at one of the three pre-defined time points of 30, 60 and 90 minutes after the procedure will be used for this.

Secondary Outcomes

  • - Pain scores based on a 0-10 NRS within 90 minutes after the procedure, 6 hours after the procedure and thereafter daily up to day 14.
  • - Cumulative pain throughout 14 days based on the area under the curve of a pain versus time plot.
  • - Duration of pain, defined as the number of days until pain scores were reported to be 0 on all following days.
  • - Daily and overall use of analgesics up to day 14 post-procedurally registered in a patient diary (electronic or on paper).
  • - Incidence of adverse events related to LB administration (including allergic reactions to LB).
  • - Incidence of serious adverse events related to LB administration (including allergic reactions to LB).
  • - Length of hospital stay in days.

Investigators

Sponsor Class
Hospital/Clinic/Other health care facility
Responsible Party
Principal Investigator
Principal Investigator

Laura Boer

Scientific

Sint Antonius Ziekenhuis Stichting

Study Sites (4)

Loading locations...

Similar Trials